

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 August 2025 (28.08.2025)



(10) International Publication Number
WO 2025/179091 A3

(51) International Patent Classification:

A61K 9/20 (2006.01) C07D 311/00 (2006.01)
A61K 31/381 (2006.01) A61K 9/14 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2025/016707

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(22) International Filing Date:

21 February 2025 (21.02.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/557,163 23 February 2024 (23.02.2024) US

(88) Date of publication of the international search report:

02 October 2025 (02.10.2025)

(71) Applicant: SUMITOMO PHARMA AMERICA, INC.
[US/US]; 84 Waterford Drive, Marlborough, Massachusetts
01752 (US).

(72) Inventors: CHEN, Xiaoxia; c/o Sumitomo Pharma America, Inc., 84 Waterford Drive, Marlborough, Massachusetts 01752 (US). JAMZAD, Shahla; c/o Sumitomo Pharma America, Inc., 84 Waterford Drive, Marlborough, Massachusetts 01752 (US). SNOONIAN, John; c/o Sumitomo Pharma America, Inc., 84 Waterford Drive, Marlborough, Massachusetts 01752 (US). ZAMAN, Noreen; c/o Sumitomo Pharma America, Inc., 84 Waterford Drive, Marlborough, Massachusetts 01752 (US). ZHANG, Haitao; c/o Sumitomo Pharma America, Inc., 84 Waterford Drive, Marlborough, Massachusetts 01752 (US).

(74) Agent: FREDERICKS, Kellie; Heslin Rothenberg Farley & Mesiti P.C., 5 Columbia Circle, Albany, 12203 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: ULOTARONT HYDROCHLORIDE MANUFACTURING PROCESS

(57) Abstract: This disclosure provides improved methods of manufacturing ulotaront HCl, for reducing impurities in ulotaront HCl, and for processing ulotaront HCl into finished dosage forms.

WO 2025/179091 A3